Update on prevention and treatment of viral hepatitis in children

Current Opinion in Pediatrics

Volumn 11, Issue 5, 1999, Pages 384-389

  Sokal, Etienne M ^a   Bortolotti, Flavia ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE; INTERFERON; LAMIVUDINE; RIBAVIRIN;

CHILD; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; PRIORITY JOURNAL; REVIEW; VACCINATION; VERTICAL TRANSMISSION; VIRUS HEPATITIS;

CHILD; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMANS; INTERFERONS; LAMIVUDINE; MALE; VIRAL HEPATITIS VACCINES;

EID: 0032825143     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199910000-00003     Document Type: Review

References (43)

1. Hutin YJF, Poof V, Cramer EH, Nainan OV, Weth J, Williams IT, et al.: A multistate foodborne outbreak of hepatitis A. N Engl J Med 1999, 340:595-602. A large outbreak of hepatitis A occurred in Michigan with sporadic cases occurring in neighbor states. Using genetic sequencing, the authors demonstrated that both hepatitis A cases from the outbreak and hepatitis A cases in other slates had identical viral RNA sequences, thereby linking the Michigan outbreak with those in the other states. This hepatitis A outbreak was associated with consumption of frozen strawberries from the same processor, served in schools. The strawberries had been contaminated before freezing, possibly during harvest.
2. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286-290.
3. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al.: Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998, 27:881-886.
4. Debray D, Cullufi P, DeVictor D, Fabre M, Bernard O: Liver failure in children with hepatitis A. Hepatology 1997, 26:1018-1022.
5. Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al.; The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategios. J Infect Dis 1998, 178:1579-1584.
6. Sagliocca L, Amoroso P, Stroffolini T, Adamo B, Tosti ME, Lettieri G, et al.: Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 1999, 353:1136-1139. This is a randomized, controlled trial of hepatitis A vaccine in 146 households in which sporadic hepatitis A cases occurred. Secondary cases occurred in 2.8% of households in which household members were vaccinated, group, versus 13.3% of households in which household members were not unvaccinated. One secondary infection was prevented for every 18 individuals vaccinated.
7. Zimmerman RK, Mieczkowski TA: How important is early childhood hepatitis B vaccination? a survey of primary care physicians, J Fam Pract 1998, 47:370-374.
8. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al.; High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999, 30:715-721.
9. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.
10. Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, et al.: Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999, 103:141-147.
11. Tang JR, Hsu H, Lin H, Ni YH, Chang M: Hepatitis B surface antigenemia at birth: a long term follow up study. J Pediatr 1998, 133:374-377.
12. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS: Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998, 178:954-959.
13. El-Serag H, Mason AC; Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
14. Ince N, Wands JR: The increasing incidence of hepatocellutar carcinoma. N Engl J Med 1999, 340:798-799. Using surveillance data analysis, these authors show a progression of the incidence of hepatocellular carcinoma in the United States from 1.4 cases per 100,000 people (1976-1980) to 2.4 cases per 100,000 people (1991-1995), with a shift toward infection in younger people. Hepatitis B and C are the putative risk factors. This rising incidence could be related to the cohort of people infected by hepatitis B and C virus during the true needle sharing, intravenous drug use, and contaminated blood products of the 1960s and 1970s.
15. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998, 28:930-938. This is a prospective evaluation of 2215 patients with viral hepatitis. The median observation period was 4.1 years. Chronic hepatitis B developed to cirrhosis in 10.2% of 610 adult patients. The cumulative progression rate to cirrhosis reached 21% after 10 years and 37% after 15 years, whereas the amount of alcohol intake was shown to be an independent factor of progression to cirrhosis.
16. Wong JB: Interferon treatment for chronic hepatitis B: costs and effectiveness. Acta Gastroenterol Belg 1998, 61:238-242.
17. Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, et al.: Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998, 29:184-190. Mediterranean children were followed for an average of 13 years, some of them treated. The majority of these children had postnatal contamination. Of these, 84% cleared HBs ag on follow-up but only 6% lost HBs ag. Hepatitis relapse was observed after HBe ag loss in nine patients, some of them being infected with HBe minus precore mutants. Two patients developed hepatocellular carcinoma.
18. Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PJ, Chen PJ, et al.: Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis Be seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998, 28:915-922.
19. Omata M: Treatment of chronic hepatitis B infection. N Engl J Med 1998, 339:114-115.
20. Sokal EM, Conjeevaram H, Roberts E, Alvarez F, Bern E, Goyens P, et al: Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998, 114:988-995. The largest ever published, randomized, controlled trial of interferon for the treatment of chronic hepatitis B in children. Interferon, given at a dosage of 6 MU 3 times per week for 6 months, was able to promote HBe ag and HBs ag loss in 28% of treated patients versus 11% of untreated patients at 1 year. At 18 months, 33% of treated patients had lost HBe ag. This was accompanied by normalization of transaminases and improvement of histology. HBs ag loss was achieved in 10% of treated children versus 1% of untreated children.
21. Lai CL, Chine RN, Leung NWY, Chang IT, Guan R, Tai DI, et al.: A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61-68.
22. Conjeevaram HS: Therapy for chronic hepatitis B: nucleoside analogues in adult and pediatric patients. Acta Gastroenterol Belg 1998, 61:224-227.
23. Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson P, Boxall E, Kelly D: Dose-finding and safety of lamivudine (LAM) in children and adolescents with chronic hepatitis B [abstract]. Hepatology 1998, 28(suppl):1306.
24. Lu SN, Chen HC, Tang CM, Wu MH, Yu ML, Lu CF, et al.: Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. Pediatr Infect Dis 1998, 17:142-145.
25. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, Vierucci A: Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1; BMJ 1998, 317:437-440. This study includes a large number of mother-infant pairs, which allows statistical analysis of variables associated with transmission (with the exclusion of HIV coinfection).
26. Kumar RM, Shahul S: Role of breast-feeding in transmission of hepatitis C virus to infants of HIV-infected mothers. J Hepatol 1998, 29:191-197.
27. Wejstal R, Widell A, Norkrans G: HCV-RNA levels increase during pregnancy in women with chronic hepatitis C. Scand J Infect Dis 1998, 30:111-113. These authors show that HCV RNA levels increase at the end of pregnancy, thus possibly favoring transmission.
28. Mazza C, Ravaggi A, Rodella A, Padula D, Muse M, Lomini M, et al., for the Study Group of Vertical Transmission: Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. J Med Virol 1998, 54:12-19.
29. Papaevangelou V, Pollack H, Rochford G, Kokka R, Hou Z, Chernoff D, et al.; Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. J infect Dis 1998, 178:104-152.
30. Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, et al.: Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998, 133:378-381. These authors show that after the disappearance of posttransfusion hepatitis, vertical transmission is the main route of the spread of HCV during childhood.
31. American Academy of Pediatrics, Committee on Infectious Diseases: Hepatitis C virus infection. Pediatrics 1998, 101:481-485.
32. Davison SM, Skidmore SJ, Collingham KE, Irving WL, Hubscher SG, Kelly DE: Chronic hepatitis in children after liver transplantation: role of hepatitis C virus and hepatitis G virus infections. J Hepatol 1998, 28:764-770.
33. Mc Diarmid SV, Conrad A, Ament ME, Vargas J, Martin MG, Goss JA, Busuttil RW: De novo hepatitis C in children after liver transplantation. Transplantation 1998, 66:311-318. These authors analyze prevalence and outcome of de novo HCV infection in relation to interferon treatment.
34. Thomas SL, Newel ML, Peckham CS, Ades AE, Hall AJ: A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998, 27:108-117.
35. Ebeling F: Epidemiology of the hepatitis C virus. Vox Sang 1998, 74:143-146.
36. Bernard O: Mother-to-infant transmission of hepatitis C. Acta Gastroenterol Belg 1998, 61:192-194.
37. Jonas MM, Ott MJ, Nelson S, Badizadegan K, Perez-Atayde A: Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J 1998, 17:241-246.
38. Vegnente A, Iorio R, Pensati P: Treatment of pediatric hepatitis C: results and perspectives. Acta Gastroenterol Belg 1998, 61:235-236.
39. Sawada A, Tajiri H, Kozaiwa K, Guo W, Tada K, Etani Y, et al.: Favorable response to lymphoblastoid interferon alpha in children with chronic hepatitis C. J Hepatol 1998, 28:184-188.
40. al-Tawil Y, Nelson C: Interferon treatment of children with chronic hepatitis C. Hepatogastroenterology 1998, 345:541-548.
41. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492. These authors provide clear data on a large series of naive patients with chronic hepatitis C in two groups: one group treated with monotherapy (interferon alfa-2b), compared with a second group treated with a combination of interferon alfa-2b and ribavirin.
42. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998, 339: 1493-1499. The authors of this large study demonstrate that combination treatment is superior to interferon monotherapy in the retreatment of patients in whom chronic hepatitis C has relapsed.
43. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999, 353:359-363.